NASDAQ:PTGX
Protagonist Therapeutics Inc Stock News
$28.15
+0.440 (+1.59%)
At Close: May 31, 2024
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
07:30am, Wednesday, 16'th Dec 2020
NEWARK, Calif., Dec. 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-77
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
11:10pm, Thursday, 10'th Dec 2020
NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwr
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
07:30am, Thursday, 10'th Dec 2020
NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public of
NEWARK, Calif., Dec. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the results of a large-scale analysis of real world treatment patterns for polycythemia vera,
NEWARK, Calif., Dec. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced additional updated results from the ongoing Phase 2 study of PTG-300 in patients with polycyth
Protagonist Therapeutics Reports Granting of Inducement Award
04:30pm, Tuesday, 01'st Dec 2020
NEWARK, Calif., Dec. 1, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 30, 2020, it issued an inducement award to Michelle Landolfi, Ph.D., the Compa
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
04:30pm, Wednesday, 11'th Nov 2020
NEWARK, Calif., Nov. 11, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fir
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
04:54pm, Wednesday, 04'th Nov 2020
NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate
NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for Hematolo
Protagonist Therapeutics Reports Granting of Inducement Award
06:27pm, Friday, 30'th Oct 2020
NEWARK, Calif., Oct. 30, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on October 31, 2020, it issued an inducement award to Nora Boyer, the Company's recently
